|
 
- 现金
- 2481 元
- 精华
- 5
- 帖子
- 855
- 注册时间
- 2002-3-30
- 最后登录
- 2012-7-8
|
1楼
发表于 2002-4-28 23:54
Viral hepatitis - CURRENT OPINION IN GASTROENTEROLOGY 2002
--------------------------------------------------------------------------------
Date: Thu, 18 Apr 2002 04:58:34 -0400
--------------------------------------------------------------------------------
Viral hepatitis
Ricardo Marrero, MD; Eugene Schiff, MD
Center for Liver Diseases, University of Miami School of Medicine, Miami,
Florida, USA. ;18:330-333
Viral hepatitis affects millions of people worldwide, making it one of the
most important diseases in the field of hepatology. The response to the hepatitis A vaccine is optimal when targeted to patients with chronic hepatitis before development of hepatic decompensation. A new triple antigen vaccine for hepatitis B virus produces a greater degree of protection.
Lamivudine can achieve a 3-to 4-log reduction in serum viral levels in
patients with chronic hepatitis B infection. Lamivudine-resistant mutants appear in more than 50% of patients after prolonged treatment. Entecavir can be given safely for a short time and causes a pronounced reduction in hepatitis B viral DNA levels with slower rebound after stopping therapy than has been reported with lamivudine. Pegylated interferon has sustained absorption, a slower rate of clearance and a longer half-life than unmodified interferon alfa. Pegylated interferon alfa-2a administered once weekly is more effective than standard interferon alfa-2a administered three
times weekly. In patients with chronic hepatitis C infection, the most
effective therapy is the combination of pegylated interferon plus ribavirin. Other major advances in the field of viral hepatitis during the past year are highlighted.
Correspondence to Eugene Schiff, MD, Center for Liver Diseases, Jackson Medical Towers, 1500 NW 12 th Ave., Suite 1101 East Tower, Miami, FL 33136, USA; e-mail: [email protected]
Curr Opin Gastroenterol 2002 May;18(3):330-333
Copyright © 2002 Lippincott Williams & Wilkins
All rights reserved
|
|
